Discover
NAMS
NewAmsterdam Pharma Company N.V.
35.17
2 x 25.05
2 x 43.94
bid
ask
+
1.28
3.78%
2 @ 04:00 PM
35.17 +0.00 (0.00%)
| Ytd | 0.26% | |
| 1y | 93.03% |
34.06
day range
35.40
18.07
52 week range
42.20
| Open | 34.33 | Prev Close | 33.89 | Low | 34.06 | High | 35.40 | Mkt Cap | 4.11B |
| Vol | 867.67K | Avg Vol | 1.29M | EPS | -1.78 | P/E | N/A | Forward P/E | -27.63 |
| Beta | 0.08 | Short Ratio | 7.09 | Inst. Own | 106.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 32.68 | 200-d Avg | 33.56 | 1yr Est | 49.46 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-07 | 2026-03 | 0 | N/A | 0.06 | 13.04% |
| 2026-02-18 | 2025-12 | 0 | N/A | -0.23 | -57.50% |
| 2026-02-18 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-05 | 2025-09 | 0 | N/A | -0.03 | -7.89% |
| 2025-11-05 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-06 | 2025-06 | 0 | N/A | 0.37 | 71.15% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-30 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-02-19 | Guggenheim | Upgrade | Buy | Buy |
| 2026-02-18 | Needham | Upgrade | Buy | Buy |
| 2026-01-21 | RBC Capital | Upgrade | Outperform | Outperform |
| 2025-12-16 | Stifel | Upgrade | Buy | Buy |
| 2025-12-02 | Goldman Sachs | Upgrade | Neutral | Neutral |
Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-01-06 | AUDET JULIETTE BERANGERE | Officer | 15.10K | Stock Award(Grant) |
| 2026-03-01 | DAVIDSON MICHAEL H | Chief Executive Officer | 174.14K | Sale |
| 2024-12-29 | FORGROWTH NAP B.V. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2025-01-06 | JONES WILLIAM A JR | Officer | 43.00K | Stock Award(Grant) |
| 2026-03-08 | KASTELEIN JOHANNES JACOB PIETER | Officer and Director | 0.00 | Sale |
| 2025-07-15 | KLING DOUGLAS F | Chief Operating Officer | 44.00K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 16.94M | 595.91M | 14.49% |
| 2026-03-30 | Capital World Investors | 11.11M | 390.70M | 9.50% |
| 2026-03-30 | RA Capital Management, L.P. | 9.55M | 335.88M | 8.17% |
| 2026-03-30 | FCPM III Services B.V. | 9.20M | 323.53M | 7.87% |
| 2026-03-30 | FMR, LLC | 8.77M | 308.29M | 7.50% |
| 2026-03-30 | Bain Capital Life Sciences Investors, LLC | 7.31M | 256.97M | 6.25% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | SmallCap World Fund Inc | 8.40M | 295.29M | 7.18% |
| 2026-04-29 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.43M | 120.49M | 2.93% |
| 2026-05-30 | Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 2.01M | 70.86M | 1.72% |
| 2026-05-30 | Fidelity Contrafund | 1.58M | 55.73M | 1.36% |
| 2026-03-30 | NEW ECONOMY FUND | 957.48K | 33.67M | 0.82% |
| 2026-05-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 690.00K | 24.27M | 0.59% |